Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$75,900.00-1.51%ETH$2,404.54-3.20%GOLD$4,387.30+1.26%OIL$103.71-2.00%
Smart Investors Daily
IP

NASDAQ · IPHA

Innate Pharma S.A.

Healthcare · Biotechnology

$1.86

Up+$0.01 (+0.54%)

Updated Sep 16, 2026, 11:06 AM

SID Score

5.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
159.21M
P/E ratio
-3.1
Dividend yield
0.00%
52-week range
$1.17 – $2.71
Volume
47.79K
Avg. volume
194.86K

Price performance

IPHA price history

1M range · 20 trading sessions · Daily adjusted prices

IPHA closed at $1.86 after 20 trading sessions, down 10.14% for the selected period.

Last close
$1.86
Period change
-10.14%
Period low
$1.85
Period high
$2.27
Daily close
View OHLC price history
IPHA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$1.85$1.92$1.84$1.8647.79K
Sep 14, 2026$1.86$1.90$1.813$1.8520.79K
Sep 11, 2026$1.89$1.93$1.87$1.878.32K
Sep 10, 2026$1.91$1.94$1.88$1.888.47K
Sep 9, 2026$2.01$2.04$1.95$1.9524.04K
Sep 8, 2026$2.04$2.06$2.00$2.0527.54K
Sep 4, 2026$2.10$2.15$2.0258$2.088.98K
Sep 3, 2026$2.14$2.20$2.09$2.1110.89K
Sep 2, 2026$2.23$2.23$2.12$2.1717.4K
Sep 1, 2026$2.1401$2.1401$2.11$2.1216.66K
Aug 31, 2026$2.21$2.2899$2.17$2.179.96K
Aug 28, 2026$2.26$2.2895$2.22$2.2211.8K
Aug 27, 2026$2.22$2.26$2.22$2.236.06K
Aug 26, 2026$2.22$2.25$2.16$2.1620.47K
Aug 25, 2026$2.2201$2.28$2.21$2.2727.97K
Aug 24, 2026$2.21$2.28$2.18$2.20558.94K
Aug 21, 2026$2.24$2.30$2.20$2.2644.36K
Aug 20, 2026$2.14$2.16$2.05$2.0952.55K
Aug 19, 2026$2.11$2.13$2.09$2.1227.07K
Aug 18, 2026$2.13$2.13$2.04$2.0746.49K

Latest IPHA news

The latest Smart Investors Daily articles mentioning IPHA.

Stock researchCompany · Overview

IPHA research

Overview

Company profile and research snapshot.

Company profile

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$3.50
Implied upside
—
Analysts
9
IPHA recent ratings
DateFirmRatingTarget
Jun 22, 2026ODDO BHFBuy—
May 14, 2026H.C. WAINWRIGHT & CO., LLCBuy—
Apr 6, 2026PORTZAMPARC BNP PARIBASBuy—
Jan 26, 2026PORTZAMPARC BNP PARIBASBuy—
Jan 19, 2026PORTZAMPARC BNP PARIBASBuy—
Open full forecast

News briefing

No generated briefing is available yet.

businesswire.com · Dec 11, 2025

Innate Pharma Releases Its 2026 Financial Calendar

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2026 financial calendar: March 26, 2026: Publication of 2025 financial statements May 13, 2026: Publication of revenue and cash position for 1Q2026 May 21, 2026: Annual General Shareholders Meeting September 17, 2026: Publication of half year financial statements November 5, 2026: Publication of revenue and cash position for 3Q2026 All financia.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By